drugset / Trial / NCT05887219

Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma

NCT05887219

Phase 1 Completed 50 enrolled Combined Military Hospital Abbottabad
RandomizedParallel-groupOpen-labelTreatment

Summary

Methodology: Fifty female patients presented with melasma (symmetrically distributed hyperpigmented macules and patches on the face) diagnosed by consultant dermatologist on clinical presentation were included in this study. The sample size was calculated by WHO Sample Size calculator taking 31% proportion of excellent response with 4% hydroquinone as an adjuvant to oral tranexamic acid as compared to 2.25% proportion of excellent response with 20% azelaic acid, 80% power of test and 5% significance level. After randomization, patients were divided into two groups. Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily) while group B was managed with topical 20% azelaic acid (daily at night) for six months. Clinical evaluation was done initially at the start of therapy and then at 2nd, 4th and 6th month using MASI score and patient's response. Efficacy was assessed in both groups at the end of therapy after six months.

Timeline

Start
2022-11-01
Primary completion
2023-04-30
Completion
2023-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azelaic acid Small molecule 20 % Other
Comparator Hydroquinone Small molecule 4 % Other
Comparator Tranexamic Acid Small molecule 250 mg Oral